Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4349836 | 0.81 | ELANE (0.32) | — | |
| SCHEMBL1502043 | 0.80 | — | — | |
| SCHEMBL2294883 | 0.80 | ALDH1A1 (0.33) | LMNA | |
| Hydrochloric Acid SCHEMBL11629040 | 0.78 | LMNA (0.32) | LMNA | |
| SCHEMBL7940239 | 0.78 | — | — | |
| SCHEMBL20118113 | 0.78 | TSHR (0.43) | LMNA | |
| SCHEMBL29001764 | 0.78 | — | — | |
| SCHEMBL10898329 | 0.76 | — | — | |
| SCHEMBL10455575 | 0.76 | — | — | |
| SCHEMBL11592647 | 0.76 | HCAR2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364159-A1 | DEUTERATED MACROCYCLIC INHIBITORS OF VIRAL NS3 PROTEASE | CONCERT PHARMACEUTICALS, INC. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110196012-A1 | DEUTERATED MACROCYCLIC INHIBITORS OF VIRAL NS3 PROTEASE | CONCERT PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | US | disclosed |
| WO-2010048468-A1 | DEUTERATED MACROCYCLIC INHIBITORS OF VIRAL NS3 PROTEASE | CONCERT PHARMACEUTICALS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-6444825-B1 | CHEMICAL INTERMEDIATE FOR TAXOL | AVENTIS PHARMA S.A. (FR) | 2002-09-03 | — | — | US | disclosed |
| US-6043375-A | Process for the preparation of an oxazolidinecarboxylic acid which is useful for preparing therapeutically active taxoids | RHONE-POULENC RORER S.A. (FR) | 2000-03-28 | — | — | US | disclosed |
| US-4960881-A | REACTING AMINO ACID WITH ALPHA-CHLORINATED CARBONATE IN SOLVENT IN PRESENCE OF ACID SCAVENGER | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1990-10-02 | — | — | US | disclosed |
| US-4652665-A | BLOCK AMINE FUNCTION OF AMINO ACIDS; PEPTIDE SYNTHESIS | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1987-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196012-A1 | DEUTERATED MACROCYCLIC INHIBITORS OF VIRAL NS3 PROTEASE | DPP3, SPINT2, DPP4 | LMNA 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.